Sangamo Therapeutics (SGMO)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
0.8200 -0.0373 (-4.35%) 03/28/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 0.8200 unch (unch) 19:55 ET
for Fri, Mar 28th, 2025
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
Cash Flows From Operating Activities | |||||
Net Income | -97,941 | -74,545 | -85,217 | -49,089 | -257,831 |
Depreciation Amortization | 9,088 | 6,953 | 4,826 | 2,253 | 109,348 |
Income taxes - deferred | N/A | 18 | N/A | N/A | -6,335 |
Accounts receivable | 397 | -9,171 | 712 | 586 | 2,755 |
Other Working Capital | 3,951 | -10,830 | -6,358 | -8,895 | -160,303 |
Other Operating Activity | 17,366 | 23,787 | 10,490 | 6,482 | 87,524 |
Operating Cash Flow | $-67,139 | $-63,788 | $-75,547 | $-48,663 | $-224,842 |
Cash Flows From Investing Activities | |||||
Change In Deposits | 35,840 | 35,840 | 35,840 | 35,840 | 174,686 |
PPE Investments | -267 | 360 | N/A | N/A | -21,155 |
Purchase Of Investment | N/A | N/A | 127 | N/A | N/A |
Other Investing Activity | 1,951 | 0 | 0 | 0 | 0 |
Investing Cash Flow | $37,524 | $36,200 | $35,967 | $35,840 | $153,531 |
Cash Flows From Financing Activities | |||||
Common Stock Issued | 29,281 | 22,070 | 22,070 | 22,524 | 16,041 |
Other Financing Activity | -904 | -684 | -481 | -402 | -1,453 |
Financing Cash Flow | $28,377 | $21,386 | $21,589 | $22,122 | $14,588 |
Exchange Rate Effect | -2,048 | 199 | -927 | -670 | 1,483 |
Beginning Cash Position | 46,704 | 46,704 | 46,704 | 46,704 | 101,944 |
End Cash Position | 43,418 | 40,701 | 27,786 | 55,333 | 46,704 |
Net Cash Flow | $-3,286 | $-6,003 | $-18,918 | $8,629 | $-55,240 |
Free Cash Flow | |||||
Operating Cash Flow | -67,139 | -63,788 | -75,547 | -48,663 | -224,842 |
Capital Expenditure | -267 | -115 | N/A | 0 | -21,155 |
Free Cash Flow | -67,406 | -63,903 | -75,547 | -48,663 | -245,997 |